Effervescent Patents (Class 424/466)
-
Publication number: 20140271849Abstract: The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Siva N. Raman, Jae Han Park, Sunil K. Battu, Eric A. Burge, David W. Bogan
-
Patent number: 8821928Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.Type: GrantFiled: June 4, 2008Date of Patent: September 2, 2014Assignee: Egalet Ltd.Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
-
Patent number: 8771648Abstract: There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.Type: GrantFiled: July 27, 2012Date of Patent: July 8, 2014Assignee: Rigel Pharmaceuticals, Inc.Inventors: Bindhumadhavan Gururajan, Farhan Abdul Karim Alhusban, Ian Paul Gabbott, David Bradley Brook Simpson, Dawn Sievwright
-
Patent number: 8765100Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.Type: GrantFiled: April 24, 2009Date of Patent: July 1, 2014Assignee: Cephalon, Inc.Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
-
Patent number: 8753611Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.Type: GrantFiled: May 2, 2011Date of Patent: June 17, 2014Assignee: Cephalon, Inc.Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
-
Patent number: 8747894Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.Type: GrantFiled: May 8, 2012Date of Patent: June 10, 2014Assignee: Alpex Pharma S.A.Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz Ardalan
-
Publication number: 20140141078Abstract: A dissolvable tablet is disclosed. The tablet includes a front side, an obverse side and a thickness between the front side and the obverse side. The front side and obverse side have a variation of convex and concave surfaces. The convex and concave surfaces allow for a plurality of dissolvable tablets to be stacked for packaging. Further, the variation of convex and concave surfaces allow for a self-agitation when the dissolvable tablet is dissolved within a liquid.Type: ApplicationFiled: September 13, 2013Publication date: May 22, 2014Inventor: Jeffery K. Slaboden
-
Patent number: 8728441Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.Type: GrantFiled: May 2, 2011Date of Patent: May 20, 2014Assignee: Cephalon, Inc.Inventors: Jonathan D. Eichman, John Hontz, Rajendra K. Khankari, Sathasivan Indiran Pather, Joseph R. Robinson
-
Patent number: 8703183Abstract: The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.Type: GrantFiled: December 24, 2010Date of Patent: April 22, 2014Assignee: Laboratorios Silanes S.A. de C.V.Inventor: Jose Manuel FranciscoOchoa Lara
-
Patent number: 8647656Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.Type: GrantFiled: December 1, 2009Date of Patent: February 11, 2014Assignee: Aptalis Pharmatech, Inc.Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
-
Publication number: 20140030326Abstract: The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form.Type: ApplicationFiled: July 2, 2013Publication date: January 30, 2014Inventor: Mahmut BILGIC
-
Patent number: 8637076Abstract: The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.Type: GrantFiled: December 13, 2006Date of Patent: January 28, 2014Assignee: Cima Labs Inc.Inventors: Walid Habib, Bhaveshkumar Kothari
-
Patent number: 8580300Abstract: The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.Type: GrantFiled: July 2, 2009Date of Patent: November 12, 2013Assignee: Dr. Falk Pharma GmbHInventors: Rudolf Wilhelm, Pröls Markus
-
Patent number: 8568775Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.Type: GrantFiled: April 2, 2007Date of Patent: October 29, 2013Assignee: Reckitt Benckiser Healthcare (UK) LimitedInventor: Paul Frederick Field
-
Publication number: 20130280326Abstract: The present invention is directed to oral pharmaceutical forms, the composition of which makes it possible to prevent possible misuse of the active principle present therein. The present invention thus relates to a pharmaceutical composition for oral administration intended to prevent abuse of use at the expense of a third party.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Annick MARTINEZ, Olivier ROUGEOT, Yoshikatsu YAGUCHI
-
Publication number: 20130280327Abstract: The present invention is directed to oral pharmaceutical forms for rapid disintegration which make it possible to prevent possible misuse of the zolpidem present therein. The present invention thus relates to a zolpidem-based orodispersible tablet formulation intended to prevent abuse of use of the tablet at the expense of a third party.Type: ApplicationFiled: June 14, 2013Publication date: October 24, 2013Inventors: Annick MARTINEZ, Olivier ROUGEOT, Yoshikatsu YAGUCHI
-
Patent number: 8545889Abstract: The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds.Type: GrantFiled: June 6, 2006Date of Patent: October 1, 2013Assignee: SPI Pharma, Inc.Inventors: Gary T. Norman, Kalyan S. Nuguru, Arun F. Amin, Sarath Chandar
-
Patent number: 8545858Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.Type: GrantFiled: April 3, 2012Date of Patent: October 1, 2013Assignee: Etex CorporationInventors: Aron D. Rosenberg, Laurent D. Gillès de Pélichy, Shrikar Bondre, Michael Strunk
-
Patent number: 8507009Abstract: This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.Type: GrantFiled: January 20, 2010Date of Patent: August 13, 2013Assignee: Salix Pharmaceuticals, Inc.Inventors: Stephen Skiendzielewski, Martin Rose, Ngoc Do
-
Publication number: 20130202699Abstract: The invention relates to a pharmaceutical composition in the form of pourable granules or a chewable tablet containing at least one phosphate binding substance and at least one effervescent agent. The composition may be taken orally without adding water.Type: ApplicationFiled: October 11, 2011Publication date: August 8, 2013Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBHInventors: Kai Strothmann, Friedrich Schulze, Johannes Bartholomaeus, Eva Fries-Schaffner, Astrid Oppermann
-
Patent number: 8486454Abstract: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic pain.Type: GrantFiled: September 29, 2006Date of Patent: July 16, 2013Assignee: Sessions Pharmaceuticals Inc.Inventors: Robert W. Sessions, Alan R. Kahn
-
Patent number: 8394409Abstract: A controlled extended drug release technology for the controlled extended release of hydrophobic or hydrophilic drugs or therapeutically active agents consisting of a homogeneous blend of one or more therapeutic agents, gas generators and surrounded by one or more layers of coat made of thermoplastic water insoluble cellulose derivatives, acrylic polymers, superdisintegrants and optionally an oil, antioxidants and electrolytes. The technology platform is capable of releasing therapeutic agents via zero, first or pseudo first order release.Type: GrantFiled: July 1, 2004Date of Patent: March 12, 2013Assignee: Intellipharmaceutics Corp.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 8343524Abstract: Provided are cap layer compositions and base layer compositions, providing quick and extended release of an active ingredient, respectively, when placed in water. Further provided are dual release compositions including a base composition and a cap composition. The base composition may include a plaster and an active agent, and it may further include at least one of a water-soluble binder, a non-water-soluble binder, and a lubricant. The cap composition may include a plaster and an active agent, and it may further include at least one of a disintegrating agent, a non-water-soluble binder, and a lubricant. The compositions may be heated and mixed and formed into a tablet. Further provided are methods of making the compositions. Further provided are methods of controlling or eliminating pests and methods of increasing the potability of water. The compositions are effective for controlling or eliminating pests such as mosquitoes when applied at an application site.Type: GrantFiled: July 31, 2009Date of Patent: January 1, 2013Assignee: Clarke Mosquito Control Products, Inc.Inventors: Michael Dean Willis, Marie Elizabeth Saunders
-
Patent number: 8343543Abstract: Pharmaceutical compositions that contain a lipase inhibitor having a melting point ?37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.Type: GrantFiled: August 19, 2011Date of Patent: January 1, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Karsten Maeder, Rainer Eugen Martin, Susanne Raab, Lukas Christoph Scheibler, Thomas Schindler, Marco Schroeder
-
Patent number: 8343917Abstract: This invention relates to a combination of erythropoietin glycoisoforms, wherein such glycoisoforms may include a quantity of sialic acid ranging from 4 to 10 molecules of sialic acid per molecule of erythropoietin. The combination of glycoisoforms can be used for the treatment or prevention of sepsis, and used to prepare a pharmaceutical composition including such combination. The invention also encompasses a cell line producing a combination of erythropoietin glycoisoforms, procedures to obtain the cell line, a procedure to produce such a combination of glycoisoforms, and methods of treatment and prevention of sepsis.Type: GrantFiled: November 7, 2006Date of Patent: January 1, 2013Assignee: Protech Pharma, SAInventors: Ricardo Agustin Lopez, Marcelo Gustavo Daelli, Dardo Alexis Pereira Bacci, Gabriel Ignacio Amadeo, Miriam Patricia Pereiro, Cristina Noemi Artana, Nestor Maskin, Bernardo Cesar Pistillo, Carolina Didier, Marina Etcheverrigaray, Ricardo Kratje
-
Patent number: 8337889Abstract: A smectite dispersible tablet and the preparation progress thereof are disclosed, which is a new pharmaceutical formulation of smectite comprising smectite, a filler and a disintegrant. The dispersible tablet is stable in quality, can disintegrate quickly and disperse homogeneously, which is easy in dosage control, convenient in transportation and packaging, and has a flavor taste, a smooth surface as well as a uniform color.Type: GrantFiled: May 23, 2005Date of Patent: December 25, 2012Assignee: Shandong Luye Pharmaceutical Co., Ltd.Inventor: Shibiao Li
-
Patent number: 8309123Abstract: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. The pharmaceutical compositions contain the at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed in a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8.Type: GrantFiled: December 19, 2008Date of Patent: November 13, 2012Inventors: Farid Bennis, Jean Jacques Serrano
-
Patent number: 8309136Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.Type: GrantFiled: March 22, 2010Date of Patent: November 13, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 8298577Abstract: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: October 30, 2012Assignee: Cephalon, Inc.Inventor: Derek Moe
-
Patent number: 8252322Abstract: The present invention is directed to a dry composition which allows delivery of active agents with good bioavailability. These compositions are prepared by emulsifying the active agent using liposome technology known in the art and then encapsulating with a modified starch. The modified starch is prepared by enzymatic hydrolysis of starch after the preparation of a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group. The resultant composition is a dry powder with excellent bioavailability. Further, the composition has good load levels and stability.Type: GrantFiled: June 3, 2003Date of Patent: August 28, 2012Assignee: Corn Products Development, Inc.Inventors: Paolo C. Trubiano, Afaf Karras
-
Patent number: 8226981Abstract: A method of preparing a taste-masking oral dosage form is provided. The method includes providing a first solution comprising a pharmaceutically active ingredient and a starch, providing a second solution comprising a hydrophilic polymer and a surfactant, blending the first and second solution to form a plurality of microparticles by a granulating process, wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch, and performing a compression-molding process to form the tablet.Type: GrantFiled: September 5, 2007Date of Patent: July 24, 2012Assignee: Medical and Pharmaceutical Industry Technology and Development CenterInventors: Chih-Chiang Yang, Wen-Che Wang, Hui-Yu Chen
-
Patent number: 8192724Abstract: A water soluble, non-abrasive, effervescent, pharmaceutically acceptable, oral care tablet for use in the oral cavity. The tablet includes a carbon dioxide source, a acid source and a tablet forming material admixed to form a chewable tablet having less than 0.2% water. The carbonate to acid ratio ranges from about 2.33:1 to about 3.33:1, the percent by weight of tablet forming material ranges from about 10% to about 70% of the total tablet weight, and the pH of the tablet when dissolved in water to form a 1.0% by weight aqueous solution ranges from about 5.0 to about 7.0. Also included is a flavor imparting flavor agent in an amount sufficient to mask taste sensations derived from the carbon dioxide source, acid source and binder to provide an abrasive-free texture to the tongue in the oral cavity. Other additives are contemplated.Type: GrantFiled: November 2, 2005Date of Patent: June 5, 2012Assignee: Tower Laboratories, Ltd.Inventor: Allen H. Rau
-
Publication number: 20120114753Abstract: The present invention provides a multi-layer tablet comprising: an effervescent layer comprising hydrochlorothiazide or amlodipine or its salt as an active ingredient, a carbonate salt, and an organic acid; and a telmisartan-containing layer.Type: ApplicationFiled: November 4, 2011Publication date: May 10, 2012Applicant: DASAN MEDICHEM CO., LTD.Inventors: Hyoung-Sun YOO, Man-Ho KWON, Young-Bin BANG, Sung-Woong KIM, Jong-Hyun LEE, Jin-Ho YOO, Bong-Haeng HUR
-
Patent number: 8168240Abstract: Disclosed is an effervescent composition that includes an effervescent agent and cranberry extract, preferably in an amount sufficient to decrease the measurable amount of bacteria present in the urine of an individual having a urinary tract infection.Type: GrantFiled: July 26, 2010Date of Patent: May 1, 2012Assignee: Amerilab Technologies, Inc.Inventors: Mary Aldritt, Robert E Lee, Fred Wehling
-
Patent number: 8158134Abstract: The invention relates to compositions in the form of microemulsion preconcentrates that contain (a) a mixture that consists of a medium-chain triglyceride and an omega-9 fatty acid and/or an omega-6 fatty acid; and (b) a surface-active component that contains a polyoxethylene tenside. When contacted with water or with an aqueous medium these microemulsion preconcentrates form microemulsions. The microemulsions of the O/W type have an average particle size below 150 nm, preferably below 100 nm. The inventive microemulsion preconcentrates and microemulsions are suitable for use as vehicles for substances, namely active agents, that are hardly soluble in water, but soluble in components (a) and/or (b). In the aqueous phase, said microemulsions may contain water-soluble substances.Type: GrantFiled: October 20, 2000Date of Patent: April 17, 2012Assignee: Vesifact AGInventors: Andreas Supersaxo, Marc Antoine Weder, Hans Georg Weder
-
Patent number: 8147860Abstract: Porous calcium phosphate implant compositions that approximate the chemical composition of natural bone mineral are provided. In addition to calcium phosphate, the compositions include an effervescent agent to promote the formation of interconnected pores and a cohesiveness agent to maintain the shape and hardness of the hardened composition. When introduced at an implant site, the calcium phosphate compositions are remodeled into bone. Methods for using the calcium phosphate compositions, e.g., to repair or replace bone, are also provided.Type: GrantFiled: December 6, 2005Date of Patent: April 3, 2012Assignee: ETEX CorporationInventors: Aron D. Rosenberg, Laurent D. Gillès de Pélichy, Shrikar Bondre, Michael Strunk
-
Patent number: 8148425Abstract: The invention relates to a pharmaceutical composition for oral or rectal administration, that contains phloroglucinol and paracetamol in a pharmaceutically acceptable carrier. The inventors have evidenced a synergy developed by these two active ingredients in antispasmodic therapy.Type: GrantFiled: February 18, 2008Date of Patent: April 3, 2012Assignee: Promindus (Actions Promotionnelles Dans l'Industrie et le Commerce)Inventors: Jean-Jacques Serrano, Claudette Serrano
-
Patent number: 8119158Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: February 21, 2012Assignee: Cephalon, Inc.Inventors: Derek Moe, Vikas Agarwal, Walib Habib
-
Patent number: 8092832Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.Type: GrantFiled: November 29, 2010Date of Patent: January 10, 2012Assignee: Cephalon, Inc.Inventors: Derek Moe, Vikas Agarwal, Walib Habib
-
Patent number: 8074305Abstract: A bubbling bath additive 42 made of a surfactant 46 and a bubbling agent 44, and a housing member 12 for housing the bubbling bath additive 42 are provided. A floating part 22, 34 that is situated above the housing member 12 and floats on the water surface, and an ejection port 33 that is provided above the waterline of the floating part 22, 34 and through which bubbles formed by the bubbling bath additive 42 are ejected outward from inside, are provided. A suction port 14 through which water flows inward from outside is provided near a lower end part of the housing member 12.Type: GrantFiled: May 26, 2005Date of Patent: December 13, 2011Assignee: Kabushiki Kaisha HealthInventor: Toyohiro Matsuda
-
Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
Publication number: 20110300216Abstract: A tablet comprising: (a) an active ingredient; and (b) at least one member of an effervescent couple, wherein said tablet dissolves in water in not more than three minutes and in the mouth in not more than thirty seconds, and wherein said tablet is capable of acting as an effervescent tablet, a rapid-dissolve tablet or a rapidly disintegrating swallow tablet.Type: ApplicationFiled: June 3, 2010Publication date: December 8, 2011Inventors: Eric R. First, Ashish Bipin Patel, Hung-Huar Tong -
Patent number: 8039508Abstract: Pharmaceutical compositions that contain a lipase inhibitor having a melting point ?37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.Type: GrantFiled: December 23, 2004Date of Patent: October 18, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Karsten Maeder, Rainer Eugen Martin, Susanne Raab, Lukas Christoph Scheibler, Thomas Schindler, Marco Schroeder
-
Publication number: 20110236481Abstract: Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight.Type: ApplicationFiled: June 9, 2011Publication date: September 29, 2011Inventor: Cédric BOURGES
-
Publication number: 20110236480Abstract: The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.Type: ApplicationFiled: April 28, 2011Publication date: September 29, 2011Applicant: RITTER PHARMACEUTICALS, INC.Inventors: Andrew J. RITTER, Dennis SAVAIANO, David BARNES, Todd KLAENHAMMER
-
Patent number: 7998500Abstract: A composition for the nutritional supplementation of women and a method of administering a composition designed for the nutritional supplementation of women is described. In accordance with one embodiment of the present invention, such a composition comprises vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, vitamin D3, vitamin C, vitamin E, niacin, copper, magnesium, zinc, and iron. In accordance with another embodiment of the present invention, a method of administering a composition designed for the nutritional supplementation of women comprises the step of administering a composition comprising vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, vitamin D3, vitamin C, vitamin E, niacin, copper, magnesium, zinc, and iron.Type: GrantFiled: August 4, 2005Date of Patent: August 16, 2011Assignee: Vertical Pharmaceuticals, Inc.Inventors: Steven A. Squashic, Kevin M. Hudy, David C. Purdy
-
Publication number: 20110189278Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.Type: ApplicationFiled: July 30, 2010Publication date: August 4, 2011Inventors: Nathan C. SCHULTHEISS, Sarah J. Bethune
-
Publication number: 20110189276Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.Type: ApplicationFiled: July 30, 2010Publication date: August 4, 2011Inventors: Nathan C. Schultheiss, Sarah J. Bethune
-
Publication number: 20110189275Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.Type: ApplicationFiled: July 30, 2010Publication date: August 4, 2011Inventors: Nathan C. SCHULTHEISS, Sarah J. Bethune
-
Publication number: 20110189277Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.Type: ApplicationFiled: July 30, 2010Publication date: August 4, 2011Inventors: Nathan C. SCHULTHEISS, Sarah J. Bethune
-
Patent number: 7972623Abstract: The invention relates to a method for producing effervescent granules, in which the reaction partners edible, organic acid components and alkaline effervescent components separating carbon dioxide are reacted with each other in a vacuum under the effect of gas in a container that can be evacuated. The container is evacuated to a first vacuum value within a vacuum range of 200-900 mbar, whereupon the pressure inside the container is increased to a second vacuum value as a result of the gases produced during the reaction. The steps are cyclically repeated while the reaction continues. A maximum number of cycles, a maximum reaction time, and optionally, a maximum load for the stirring apparatus are defined before the reaction begins, and the reaction is terminated after reaching the first of the maximums.Type: GrantFiled: August 7, 2004Date of Patent: July 5, 2011Assignee: Dr. Gergely & Co.Inventors: Irmgard Gergely, Thomas Gergely, Stefan Gergely